MAGED2 and gastric cancer: Among the combinations, we selected a dual‐marker expression panel comprising SYT8 and MAGED2. The single use of SYT8 and MAGED2 exhibited superior predictive performance compared with CEA or CA19‐9, each of which is currently used as a marker of gastric cancer.